Professional Documents
Culture Documents
Daftar Pustaka
Daftar Pustaka
Daftar Pustaka
Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman
DR, et al. Increased risk of lymphoma in sicca syndrome. Ann. Intern. Med.
2004;89(6):888-92.
De Monchy, I., Jonsson M.V., Appel, S., Jonsson R. New concepts in the
pathogenesis of Sjogrens syndrome. Rheum. Dis. Clin. North America.
2011:21(5),656-60.
Kalk, W.W., Mansour, K., Vissink, A., Spijkervet F.K., Bootsma, H., Kallenberg,
C.G.< et al. Oral and ocular manifestation in Sjogrens syndrome. J.
Rheumatology. 2002;29(5),924-30.
Foulks GN. The evolving treatment of dry eyes. Ophtalmol Clin North Am.
2003;16:29-35.
Wolkoff P, Nojgaard JK, Franck C., Skov P. The modern office environment
desiccates the eyes? Indoor Air. 2006;16:258-65.
Noble BA, Loh RS, MacLennan S, Pesudovs K, Reynolds A, Bridges LR, et al.
Comparison of autologous serum eye drops with conventional therapy in
randomized controlled crossover trial for ocular surface disease. Br J Ophtalmol.
2004;88:647-52.
Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular
surface disorder. Br J Ophtalmol 2004;88:1467-74.
Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of
Sjogrens syndrome. Clin Immunol. 2001;101:249-63.
Aikaterini TS, Judith AJ. Primary Sjogrens Syndrome: Current and Prospective
Therapies.Semin Arthritis Rheum. 2008;37:273-92.
Meijer JM, Pijpe J, Vissink A. Treatment of Primary Sjogren syndrome with
Rituximab; extended follow up, safety and efficacy of treatment. Ann. Rheum.
Dis. 2009;68:284-5.
Casals MR Font J. Primary Sjogren Syndrome: Current and emergent
aetiopathogenic concepts. Rheumatology. 2005;44:1354-67
Tsifetaki N, Kitsos CA, Paschides. Oral Pilocarpin for the treatment of ocular
symptoms in patient with Sjogren syndrome. A randomized controlled study. Ann.
Rheum Dis. 2003;62:1204-7.